Skip to main content
Top
Published in: Journal of Nephrology 7/2023

16-06-2023 | COVID-19 | original Article

Clinical efficacy of the fourth dose of the BNT162b2 vaccine in maintenance dialysis patients   

Authors: Keren Cohen-Hagai, Tzipi Hornik-Lurie, Sydney Benchetrit, Naomi Nacasch, Ayelet Grupper, Yael Einbinder, Ori Wand, Moshe Shashar

Published in: Journal of Nephrology | Issue 7/2023

Login to get access

Abstract

Background and objectives

Highly effective vaccines against severe acute respiratory syndrome virus 2 have been developed and administered worldwide. However, protection from coronavirus disease 2019 is not absolute and an optimal vaccination regimen needs to be established. This study assessed the clinical efficacy of the coronavirus disease 2019 vaccine among dialysis patients receiving 3 or 4 doses of vaccine.

Design, setting, participants, and measurements

This retrospective study was conducted using the electronic database of Clalit Health Maintenance Organization in Israel. Chronic dialysis patients treated with either hemodialysis or peritoneal dialysis during the coronavirus disease 2019 pandemic were included. We compared clinical outcomes of patients who had received three or four doses of the severe acute respiratory syndrome virus 2 vaccine.

Results

This study included 1,030 patients on chronic dialysis, with a mean age of 68 ± 13 years. Among them, 502 patients had received 3 doses of the vaccine and 528 received 4 doses. Severe acute respiratory syndrome virus 2 infection rates, severe COVID-19 that resulted in hospitalizations, COVID-19–related mortality and all-cause mortality rates were lower among chronic dialysis patients who received a fourth dose of vaccine as compared to those who received only 3 doses (after controlling for age, sex and comorbidities). Despite lower mortality rates observed with the Omicron variant, the fourth dose was significantly associated with reduced COVID-19-related mortality (1.7% vs. 3.8%, p = 0.04). Odds ratio for COVID-19-related mortality was 0.44 with 95% CI 0.2–0.98.

Conclusions

As seen in the general population and with previous vaccine boosters, the fourth dose of the BNT162b2 vaccine reduced rates of severe COVID-19-related hospitalization and mortality among chronic dialysis patients. Further studies are needed to establish the optimal regimens of vaccination for patients on chronic dialysis.

Graphical abstract

Literature
6.
go back to reference Nacasch N, Erez D, Lishner M et al (2022) Long-term antibody response to the BNT162b2 vaccine among maintenance hemodialysis patients. Am J Kidney Dis 79(1):137–139CrossRefPubMed Nacasch N, Erez D, Lishner M et al (2022) Long-term antibody response to the BNT162b2 vaccine among maintenance hemodialysis patients. Am J Kidney Dis 79(1):137–139CrossRefPubMed
18.
go back to reference Barh D, Tiwari S, Rodrigues Gomes LG et al (2022) SARS-CoV-2 variants show a gradual declining pathogenicity and pro-inflammatory cytokine stimulation, an increasing antigenic and anti-inflammatory cytokine induction, and rising structural protein instability: a minimal number genome-based approach. Inflammation. https://doi.org/10.1007/S10753-022-01734-WCrossRefPubMed Barh D, Tiwari S, Rodrigues Gomes LG et al (2022) SARS-CoV-2 variants show a gradual declining pathogenicity and pro-inflammatory cytokine stimulation, an increasing antigenic and anti-inflammatory cytokine induction, and rising structural protein instability: a minimal number genome-based approach. Inflammation. https://​doi.​org/​10.​1007/​S10753-022-01734-WCrossRefPubMed
Metadata
Title
Clinical efficacy of the fourth dose of the BNT162b2 vaccine in maintenance dialysis patients   
Authors
Keren Cohen-Hagai
Tzipi Hornik-Lurie
Sydney Benchetrit
Naomi Nacasch
Ayelet Grupper
Yael Einbinder
Ori Wand
Moshe Shashar
Publication date
16-06-2023
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 7/2023
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-023-01667-z

Other articles of this Issue 7/2023

Journal of Nephrology 7/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.